Lv3
236 积分 2025-10-27 加入
Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications
17天前
已完结
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
17天前
已完结
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
17天前
已完结
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
17天前
已完结
Patient-derived melanoma organoid models facilitate the assessment of immunotherapies
17天前
已完结
Why has immune “checkpoint” therapy failed in most clinical trials?
17天前
已完结
Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance
17天前
已完结
Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma
17天前
已完结
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
17天前
已完结
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
17天前
已完结
皖公网安备34019202002308
